Diaceutics PLC Poster presentation at ESMO
September 30 2019 - 3:01AM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
30 September 2019
Diaceutics PLC
("Diaceutics" or the "Company")
Poster presentation at ESMO
Diaceutics PLC (AIM: DXRX), the data analytics and
implementation services company which services the global
pharmaceutical industry, announces it will present a poster at the
2019 European Society of Medical Oncology Congress ("ESMO") in
Barcelona today. ESMO will run from 27 September - 1 October
2019.
ESMO is the most influential oncology meeting in Europe, in
partnership with the EACR (European Association for Cancer
Research). The ESMO Congress is the appointment in Europe for
clinicians, researchers, patient advocates, journalists and the
pharmaceutical industry from all over the world to get together,
learn about the latest advances in oncology and translate science
into better cancer patient care.
The Company will present a poster entitled "Known and unknown
gene fusion detection capabilities of solid tumour laboratories
conducting next generation sequencing in 6 countries". The Poster
focusses on the current next generation sequencing ("NGS")
capabilities in solid tumour oncology laboratories to detect
unknown gene fusions, and concludes that labs in the EU have not
kept up with the technical advances in NGS testing due to a lack of
sufficient funding, which may lead to missed opportunities for
improved treatment for patients.
The poster can be viewed via this link once it has been
presented:
http://www.rns-pdf.londonstockexchange.com/rns/0424O_1-2019-9-29.pdf
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Cenkos Securities plc (Nominated adviser
and broker) +44 (0) 20 3861 6630
Callum Davidson / Giles
Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and
implementation services provider for global pharmaceutical
companies. The Company, quoted on the Alternative Investment Market
(AIM) of the London Stock Exchange, is enabling Pharma to
accelerate their market penetration and achieve a better return on
precision medicine therapies by helping them to revolutionise
patient testing. By generating insights from its data lake of
clinical laboratory testing data and other data, Diaceutics helps
Pharma understand and leverage the diagnostic landscape through
initiatives that improve patient testing, leading to better
treatment outcomes. The Company works with more than 30 global
pharmaceutical companies across hundreds of precision medicine
projects. The Company employs a leading global group of experts
from the laboratory, diagnostic and pharmaceutical industries.
www.diaceutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKCDDKBKDPCB
(END) Dow Jones Newswires
September 30, 2019 03:01 ET (07:01 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024